F8-IL-4 是一种靶向 IL-4 的免疫细胞因子,通过结合新生血管表达的靶点将 IL-4 特异性递送至炎症部位,可通过调控 T 细胞亚群和巨噬细胞极化减轻小鼠的胶原诱导性关节炎,与 Dexamethasone (MS-E10819) 联用时能产生协同且持久的治疗效果,并通过维持抗炎细胞表型和细胞因子谱来防止停药后关节炎复发,因此可用于胶原诱导性关节炎的研究。
F8-IL-4
产品编号: MS-O87384
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价

产品描述

F8-IL-4 是一种靶向 IL-4 的免疫细胞因子,通过结合新生血管表达的靶点将 IL-4 特异性递送至炎症部位,可通过调控 T 细胞亚群和巨噬细胞极化减轻小鼠的胶原诱导性关节炎,与 Dexamethasone (MS-E10819) 联用时能产生协同且持久的治疗效果,并通过维持抗炎细胞表型和细胞因子谱来防止停药后关节炎复发,因此可用于胶原诱导性关节炎的研究。

生物实验数据

生物活性 F8-IL-4 is an IL-4-targeting immunocytokine that specifically delivers IL-4 to inflammatory sites by binding to targets expressed on neovasculature, alleviates collagen-induced arthritis in mice by modulating T cell subsets and macrophage polarization, and when combined with Dexamethasone (MS-E10819) produces synergistic and durable therapeutic effects by maintaining an anti-inflammatory cell phenotype and cytokine profile to prevent arthritis relapse after treatment withdrawal, making it useful for the study of collagen-induced arthritis.
IC50 & Target

IL-4

 

体内研究
(In Vivo)

F8-IL-4 (100 μg per mouse; intraperitoneally; on day 1, 4, and 7 post-disease onset; 10 days) 可通过调控 T 细胞亚群和巨噬细胞极化减轻 DBA/1 小鼠的胶原诱导性关节炎;当与 Dexamethasone (MS-E10819) 联用时,可产生协同且持久的治疗效果,通过维持抗炎细胞表型和细胞因子谱来防止停药后关节炎复发。

Animal Model: DBA/1 (10- to 12-week-old male; collagen-induced arthritis model)
Dosage: 100 μg per mouse
Administration: intraperitoneally; on day 1, 4, and 7 post-disease onset; 10 days
Result: Reduced arthritis scores, increased IL-4 levels in joints and serum, decreased IL-1β, IL-17A, IL-6, and GM-CSF levels in the claws, and increased TNF-α levels in the claws.
Significantly increased the total number and percentage of IL-4-secreting T_H2 cells in the joints and significantly decreased the number of IL-17A-secreting CD4+ and TCRγδ T cells.
Increased the percentage of CD206+ macrophages in the claws and decreased the percentage of macrophages expressing MHC class II molecules in the claws.
Decreased the expression of Il12b (p40) mRNA in the spleen.
Produced a synergistic therapeutic effect when used in combination with dexamethasone.
Significantly increased serum IL-10 levels when used in combination with dexamethasone.
When used in combination with dexamethasone:
Significantly decreased the levels of IL-1β, IL-6, GM-CSF, and IL-12p70 in the claws.
Significantly increased the proportion of CD25+FoxP3+ Treg cells among CD4+ T cells in the joints and significantly decreased the T_H17/Treg cell ratio.
Significantly increased the percentage of CD206+ macrophages in the claws and significantly decreased the percentage of total macrophages and macrophages highly expressing MHC class II molecules in the claws.
Significantly increased the expression of arginase 1, IL-10, and Chil3 (Ym1) mRNA in the spleen and significantly decreased the expression of Nos2 and Il12b (p40) mRNA.
Significantly decreased the total number of cells, T_H17 cells, IL-17A+ TCRγδ T cells, and neutrophils in the claws.
Significantly decreased the levels of IL-17A, IL-1β, and IL-12 in the claws and significantly increased the serum IL-10 level.
Significantly increased the percentage of CD206+ macrophages in the claws and decreased the percentage of MHC class II positive macrophages.
Significantly increased the expression of arginase 1 and IL-10 mRNA in the spleen, and decreased the expression of IL-12b (p40) mRNA.

化学信息

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础